Saxagliptin Hydrochloride Patent Expiration

Saxagliptin Hydrochloride is used for managing type II diabetes. It was first introduced by Astrazeneca Ab in its drug Onglyza on Jul 31, 2009. 6 different companies have introduced drugs containing Saxagliptin Hydrochloride.


Saxagliptin Hydrochloride Patents

Given below is the list of patents protecting Saxagliptin Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Onglyza US6395767 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method Feb 16, 2021

(Expired)

Astrazeneca Ab
Onglyza US7951400 Coated tablet formulation and method Nov 30, 2028 Astrazeneca Ab
Onglyza USRE44186 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method Jul 31, 2023

(Expired)

Astrazeneca Ab


Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳

Saxagliptin Hydrochloride Generics

Several generic applications have been filed for Saxagliptin Hydrochloride. The first generic version for Saxagliptin Hydrochloride was by Amneal Pharmaceuticals Llc and was approved on Jul 31, 2023. And the latest generic version is by Sun Pharmaceutical Industries Ltd and was approved on Jul 31, 2023.

Given below is the list of companies who have filed for Saxagliptin Hydrochloride generic.


1. AMNEAL

Amneal Pharmaceuticals Llc has filed for 2 different strengths of generic version for Saxagliptin Hydrochloride. All of these versions come by the name SAXAGLIPTIN. Given below are the details of the strengths of this generic introduced by Amneal.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 2.5MG BASE tablet Discontinued ORAL N/A Jul 31, 2023
EQ 5MG BASE tablet Discontinued ORAL N/A Jul 31, 2023


2. AUROBINDO PHARMA

Aurobindo Pharma Ltd has filed for 2 different strengths of generic version for Saxagliptin Hydrochloride. All of these versions come by the name SAXAGLIPTIN. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 2.5MG BASE tablet Prescription ORAL AB Jul 31, 2023
EQ 5MG BASE tablet Prescription ORAL AB Jul 31, 2023


3. MYLAN

Mylan Pharmaceuticals Inc has filed for 2 different strengths of generic version for Saxagliptin Hydrochloride. All of these versions come by the name SAXAGLIPTIN. Given below are the details of the strengths of this generic introduced by Mylan.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 2.5MG BASE tablet Prescription ORAL AB Jul 31, 2023
EQ 5MG BASE

(reference standard)

tablet Prescription ORAL AB Jul 31, 2023


4. GLENMARK PHARMS LTD

Glenmark Pharmaceuticals Ltd has filed for 2 different strengths of generic version for Saxagliptin Hydrochloride. All of these versions come by the name SAXAGLIPTIN. Given below are the details of the strengths of this generic introduced by Glenmark Pharms Ltd.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 2.5MG BASE tablet Prescription ORAL AB Jul 31, 2023
EQ 5MG BASE tablet Prescription ORAL AB Jul 31, 2023


5. SUN PHARM

Sun Pharmaceutical Industries Ltd has filed for 2 different strengths of generic version for Saxagliptin Hydrochloride. All of these versions come by the name SAXAGLIPTIN. Given below are the details of the strengths of this generic introduced by Sun Pharm.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 2.5MG BASE tablet Prescription ORAL AB Jul 31, 2023
EQ 5MG BASE tablet Prescription ORAL AB Jul 31, 2023